14 Neuroscience Startups To Watch In 2024

July 30, 202410 min read

Neuroscience startups are on the rise, fueled by innovations in brain-computer interfaces, neurotherapeutics, and mental health technologies. These companies are developing solutions that could transform the way we understand and treat brain disorders, offering hope to millions of people worldwide. 

Investment in neuroscience companies has surged by nearly 20% annually over the past five years. In addition to venture capital and major pharmaceutical and biotech companies, significant funding also comes from institutional investors and government grants. For example, in 2023, the NIH in the United States allocated $11.9 billion to neuroscience-related initiatives, making it one of the top-funded areas. [1]

In this article, we spotlight several leading neuroscience startups that are pioneering breakthroughs poised to fundamentally transform the approach to brain health and disease. These startups promise to improve patient outcomes and reduce healthcare costs.

Did you know?

The global neuroscience market size is projected to reach $65.2 billion by 2030, growing at a CAGR of 5.56%. This growth is primarily driven by the increasing prevalence of neurological disorders, an aging population, and the rising awareness of mental health issues. [2]

14. Qynapse 

Founded in 2015
Location: Paris, France
Total Funding: $6.6 million
Growth Status: Steady

Qynapse utilizes AI and machine learning algorithms to improve the diagnosis, prognosis, and monitoring of neurological disorders. These algorithms are trained on over 10,000 MRI and PET scan images to detect biomarkers of neurological diseases. 

Qynapse’s neuroimaging analysis platform, QyScore, is aimed at both clinical and research settings. It can provide detailed, quantitative insights into the brain, enhancing the accuracy of neurological diagnoses and the effectiveness of treatments.

In 2020, Qynapse acquired True Positive Medical Devices, a Canadian-based startup, to further improve its neurological image processing capabilities, In 2022, it partnered with Calyx, the eClinical and Regulatory solutions, to help develop new medical treatments for central nervous system disorders. [3][4]

13. AviadoBio

Founded in 2019
Location: London, United Kingdom
Total Funding: $90.67 million
Growth Status: Accelerated

AviadoBio develops innovative gene therapies for neurodegenerative diseases. It harnesses advanced gene therapy techniques to develop treatments for neurological disorders, rather than just managing symptoms. [5]

More specifically, the company uses viral vectors, such as adeno-associated viruses, to deliver therapeutic genes to specific cells in the brain. These therapies aim to halt the profession of diseases and repair damaged neurons, promoting overall brain health. 

The company is conducting rigorous preclinical studies and clinical trials to evaluate the safety and efficacy of its gene therapy candidates. In 2024, it treated the first subject in a trial of FTD-GRN therapy. To date, AviadoBio has raised nearly $90.67 million from eight major investors, including LifeArc, Advent Life Sciences, and EQT Life Sciences. [6]

12. NeuraLight

Founded in 2021
Location: Tel Aviv, Israel
Total Funding: $30.5 million
Growth Status: Accelerated

NeuraLight combines proven oculometric measurements using Machine Learning and Computer Vision techniques to yield precise markers from facial video captured with a standard camera. These markers serve as reliable proxies for traditional endpoints used in neurological assessments. [7]

By analyzing these digital markets, NeuraLight’s platform can create an accurate snapshot of an individual’s neurological status. The platform supports remote monitoring, allowing for continuous and convenient tracking of neurological status. 

The company currently targets identifying early biomarkers for ALS, Multiple Sclerosis, Parkinson’s Disease, Alzheimer’s Disease, and Mild Cognitive Impairment. In 2022, it closed the Series A round, raising $25 million from lead investor Koch Disruptive Technologies. [8]

11. Neurable

Founded in 2015
Location: Massachusetts, United States
Total Funding: $22.8 million
Growth Status: Explosive

Neurable develops brain-computer interface (BCI) technology that enables direct communication between the brain and computers. They aim to create intuitive and seamless control of devices and software using brain signals, with applications ranging from gaming and productivity tools to accessibility solutions for disabled people. 

But how does it work? Neurable leverages electroencephalography (EEG) to measure brain activity and translate it into digital commands. To do this, they use non-invasive EEG sensors embedded in headsets to capture brain signals. Then, machine learning models analyze EEG data to identify patterns associated with specific thoughts or intentions. The signals are eventually converted into actionable commands for software and devices. 

This technology has the potential to revolutionize industries by enabling mind-controlled applications, enhancing user experiences, and improving accessibility for disabled individuals. 

To date, Neurable has raised $22.8 million through 13 funding rounds. In their latest round (which occurred in 2024), they secured $13 million from Pace Ventures, Metaplanet, TRAC, and Ultratech Capital Partners. [9]

10. Arctop

Founded in 2016
Location: California, United States
Total Funding: $15 million
Growth Status: Rapid expansion

Arctop’s patented technology analyzes brain signals and generates a precise measure of the mind in real-time. It combines brainwave analysis with advanced machine learning models to interpret and respond to users’ cognitive and emotional states. [10]

This technology has the potential to make games and entertainment more engaging and personalized, setting new standards in the industry. It can also promote mental wellbeing and manage stress by monitoring mental health in real-time. 

The company has raised $15 million through three funding rounds, with the latest one (Series A) occurring in 2023. In that round, Arctop secured $10 million from lead investors Fifth Growth Fund and Supermoon Capital. [11]

9. BrainQ

Neuroscience startups - BrainQ

Founded in 2016
Location: Yerushalayim, Israel
Total Funding: $48.8 million
Growth Status: Rapid

BrainQ develops AI-powered neuro-rehabilitation therapies for people who have suffered from neurological damage, such as stroke or traumatic brain injury. Its mission is to improve recovery outcomes through personalized, non-invasive treatments that promote neuroplasticity and enhance motor and cognitive functions. 

The company utilizes machine learning models to analyze massive volumes of neurological data, detecting patterns and biomarkers associated with recovery. Its therapy involves non-invasive electromagnetic field stimulation, which targets particular brain regions to promote neuroplasticity and recovery. The treatment can be customized to the patient’s needs, with the rehabilitation process optimized based on real-time feedback and progress monitoring.

In 2023, BrainQ was featured in the Fast Company’s annual Next Big Things in tech list. In 2024, it was awarded “Best New Technology Solution – Therapeutic” in the MedTech Breakthrough Awards. [12][13]

8. Rune Labs

Founded in 2018
Location: California, United States
Total Funding: $41.3 million
Growth Status: Explosive

Rune Labs develops software and data platforms to improve the diagnosis and treatment of neurological disorders. It integrates various data sources, including brain imaging, electrophysiology, and wearable sensors to provide detailed insights into brain health. 

They aim is to bridge the gap between data collection and actionable clinical insights, supporting both clinicians and researchers.

Rune Labs has developed a software called StrivePD, which allows clinicians to track their patient’s progress and monitor changes in symptoms. In 2022, the Apple Watch-based version of this software received FDA clearance. In 2023, the company partnered with BlueRock Therapeutics for Parkinson’s research. [14][15]

In 2024, Rune Labs closed a strategic funding round of $12 million, bringing the total amount raised by the company to $41.3 million. Major investors include Nexus NeuroTech, Eclipse Ventures, DigiTx Partners, TruVenturo, and Moment Ventures.

7. CuraSen Therapeutics

Founded in 2017
Location: California, United States
Total Funding: $95.9 million
Growth Status: Rapid

CuraSen Therapeutics develops small-molecule drugs that target specific pathways involved in neurodegenerative diseases. It aims to improve the quality of life for patients suffering from disorders like Alzheimer’s disease, Parkinson’s disease, and other age-related cognitive impairments. 

The company is actively involved in clinical trials to test the safety and efficacy of its lead drug candidates. It is currently testing two agonist compounds in Phase 2 clinical studies: one in Alzheimer’s disease and one in Parkinson’s disease. [16]

Since its inception, CuraSen has raised close to $96 million from nine major investors, including New Leaf Venture Partners, Longitude Capital, Alta Partners, Silverstein Foundation, and Alzheimer’s Drug Discovery Foundation. [17]

6. MindMaze

Founded in 2012
Location: Vaud, Switzerland
Total Funding: $340.7 million
Growth Status: Accelerated

MindMaze integrates AI and VR to create immersive, interactive experiences that stimulate brain activity and promote recovery. They are focused on developing platforms that enhance neuro-rehabilitation, cognitive training, and mental health treatment.

Their VR-based neuro-rehabilitation platforms can treat conditions like traumatic brain injury, stroke, and spinal cord injuries. These platforms help individuals regain cognitive abilities and motor function through engaging, interactive exercises.  

In 2023, MindMaze introduced Izar, a first-of-its-kind peripheral device. It’s an FDA-listed CE-marked hyper-sensitive controller for people with impairment in hand motor function. It provides effective hand dexterity and strength treatment, filling a critical gap in neurological care. [18]

So far, the company has successfully delivered over 100,000 therapy sessions to patients in 19 countries. It has received eight regulatory approvals, ensuring that its products meet all safety and efficacy standards for clinical use. 

MindMaze’s intellectual property portfolio includes 60 issued and pending patents and 600+ published papers and conference proceedings. Plus, it is the first company to obtain a Category 3 code for its digital therapeutic solutions. [19]

5. Synchron

Founded in 2016
Location: New York, United States
Total Funding: $130 million
Growth Status: Explosive

Synchron develops advanced brain-computer interface (BCI) technology to enable communication and control for people with severe paralysis and other neurological conditions. It creates minimally invasive, implantable devices that convert brain signals into actionable commands, offering new levels of interaction for patients. 

Synchron’s flagship product, Stentrode, is implanted via the jugular vein and positioned in a blood vessel next to the motor cortex. It records neural signals from the brain’s surface and translates them into commands to control external devices, such as computers or assistive devices, enabling real-time control without the need for complex surgeries. [20]

In 2024, the company successfully connected its brain implant to Apple’s Vision Pro headset, allowing patients to control the device using only their thoughts. [21]

Synchron has raised a total of $130 million from 23 investors, including Subversive Capital, Bezos Expeditions, Reliance Industries, Green D Ventures, and General Advance. 

4. Inbrain Neuroelectronics

Founded in 2019
Location: Catalonia, Spain
Total Funding: $60.2 million
Growth Status: Rapid

Inbrain develops advanced neuroelectronic interfaces using graphene technology. Graphene, which is known for its exceptional electrical conductivity and biocompatibility, can be used to create electrodes that can interface with neural tissue with high precision. 

Inbrain aims to develop minimally invasive, highly precise neural devices that can be used for both diagnostic and therapeutic purposes, particularly for treating epilepsy and Parkinson’s disease. 

In 2023, the company announced that its Intelligent Network Modulation System received Breakthrough Device Designation from the FDA as an adjunctive therapy for Parkinson’s Disease. [22]

To date, Inbrain has raised over $60 million through eight funding rounds. In their latest round (Debt Financing), they secured $21.6 million from lead investor European Investment Bank.

3. Neurona Therapeutics

Founded in 2008
Location: California, United States
Total Funding: $320.3 million
Growth Status: Explosive

Neurona creates specialized neural cell therapies that can repair or replace damaged brain tissue, offering potential cures for various severe neurological conditions. It focuses on targeted delivery of neural precursor cells to specific brain regions affected by the disease. 

They have developed proprietary techniques and a regenerative medicine discovery platform to manufacture specific types of neuronal and gene-edited cell therapy candidates for targeted delivery into the damaged nervous system. 

Neurona’s lead product candidate, NRTX-1001, is being analyzed in a Phase I/II clinical trial for chronic focal epilepsy.  In 2024, the company closed the Series E round, raising $120 million from lead investors Viking Global Investors and Cormorant Asset Management. The money will be used to advance its lead candidate, NRTX-1001, and other cell therapy candidates for the treatment of chronic neurological disorders. [23][24]

2. Kernel

Founded in 2016
Location: California, United States
Total Funding: $158.2 million
Growth Status: Rapid

Kernel develops non-invasive brain-recording devices to capture and interpret neural activity with high precision. These devices collect massive volumes of neural data efficiently, facilitating large-scale studies and applications. 

Kernel’s flagship product, Flow2, is a helmet-like device that utilizes time-domain functional near-infrared spectroscopy (TD-fNIRS) to measure changes in blood oxygenation, which is a proxy for neural activity. The device can achieve a sampling rate of 3.7 Hz, enabling fast whole-head hemodynamic imaging and providing detailed insights into brain function. [25]

The company has raised over $158 million from six major investors: General Catalyst, Tiny Blue Dot, Eldridge Industries, Khosla Ventures, Manta Ray Ventures, and Bryan Johnson. [26]

1. Neuralink

Founded in 2016
Location: Catalonia, Spain
Total Funding: $686.2 million
Growth Status: Explosive

Co-founded by Elon Musk, Neuralink develops brain-machine interfaces that can facilitate direct communication between the human brain and computers. The company’s mission is to treat neurological conditions, improve human cognitive abilities, and eventually achieve a symbiosis between humans and artificial intelligence. 

Neuralink has developed a small, implantable device called the “N1 Implant,” which consists of 1,024 electrodes distributed across 64 flexible threads. It can be inserted into the brain to detect and record neural activity.

A highly advanced surgical robot implants this device with high precision and minimal damage to brain tissue. Once implanted, it communicates wirelessly with external devices, enabling real-time data transmission and interaction.

In January 2024, Neuralink successfully implanted this device in its first human patient. The patient has made a full recovery and is able to play online chess and Sid Meier’s Civilization VI, a turn-based strategy game. In May 2024, Neuralink received FDA approval to proceed with a second brain implant. [27][28]

Read More

Sources Cited and Additional References

  1. Pharmaceutical Products & Market, Total neuroscience funding by the NIH from FY 2013 to FY 2025, Statista
  2. Medical Devices, Neuroscience market size, share & trends analysis, Grand View Research
  3. Junji Nishihata, McGill brain-scanning spinoff acquired by French firm, McGill
  4. Calyx, Calyx and Qynapse partnering to enable AI-enhanced Medical imaging services, PR Newswire
  5. AviadoBio, Revolutionary gene therapies for neurodegenerative disorders, Nature
  6. Company Overview, AviadoBio’s funding and financials, Crunchbase
  7. Marisa Wexler, Measuring eye movements may help track Parkinson’s progression, Parkinson’s News Today
  8. Startups, NeuraLight secures $25 million Series A to develop precision medicine for neurological diseases, Calcalistech
  9. AI, Neurable raises $13M for brain-computer interface with everyday products, Venture Beat
  10. Ronen Kopito, Brain-based authentication: Towards a scalable, commercial-grade solution using noninvasive brain signals, BioRxiv
  11. Arctop, The company announces $10m series A funding, PR Newswire
  12. List, Next big things in tech 2023, FastCompany
  13. Press Release, Best new tech solution – Therapeutic in the 2024 MedTech Breakthrough Awards, BrainQ
  14. Nicole Wetsman, Rune Labs’ Apple Watch-based Parkinson’s disease tracker gets FDA clearance, TheVerge
  15. Jessica Hagen, Rune Labs partners with biopharma company for Parkinson’s research, MobiHealthNews
  16. About page, Targeting neurodegeneration with novel science, CuraSen
  17. Company Overview, CuraSen Therapeutics’ funding and financials, Crunchbase
  18. Press Release, The first-in-class smart peripheral for hand dexterity assessment and training, MindMaze
  19. Homepage, Pioneering digital neurotherapeutics, MindMaze
  20. Tech, Synchron’s BCI aims to restore the control of a touchscreen for patients with limited hand mobility, Synchron
  21. Ashley Capoot, Neuralink rival Synchron’s brain implant now lets people control Apple’s Vision Pro with their minds, CNBC
  22. InBrain Neuroelectronics, Company announces FDA breakthrough, Businesswire
  23. Our Pipeline, Novel neural cell therapy candidates for chronic neurological disorders, Neurona Therapeutics
  24. Tristan Manalac, Neurona raises $120m, buoyed by early-stage data for epilepsy cell therapy, BioSpace
  25. Tech, Detailed maps of the key patterns of activity in the brain, Kernel
  26. Company Overview, Kernel’s funding and financials, Crunchbase
  27. Press Release, PRIME study progress update, Neuralink
  28. Rolfe Winkler, Elon Musk’s Neuralink gets FDA green light for second patient, as first describes his emotional journey, WSJ
Written by
Varun Kumar

I am a professional technology and business research analyst with more than a decade of experience in the field. My main areas of expertise include software technologies, business strategies, competitive analysis, and staying up-to-date with market trends.

I hold a Master's degree in computer science from GGSIPU University. If you'd like to learn more about my latest projects and insights, please don't hesitate to reach out to me via email at [email protected].

View all articles
Related articles
Leave a reply